IMV Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA Across Five Solid Tumor Indications

Biotech Investing

IMV (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with select advanced or recurrent solid tumors. As quoted in the press release: …

IMV (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with select advanced or recurrent solid tumors.

As quoted in the press release:

“The clinical data from our recent ASCO meeting presentation demonstrated for the first time the unique potential of DPX-Survivac to generate solid tumor regressions in ovarian cancer,” said Frederic Ors, Chief Executive Officer, IMV Inc. “We are delighted to expand our clinical program and collaboration with Merck across multiple cancer indications, and look forward to investigating the potential added benefit of combining DPX-Survivac and KEYTRUDA®.”

The open-label, multicenter, Phase 2 basket study will evaluate the safety and efficacy of the immunotherapeutic combination agents in patients with bladder, liver (hepatocellular carcinoma), ovarian, or non-small cell lung (NSCLC) cancers as well as tumors shown to be positive for the microsatellite instability high (MSI-H) biomarker. Investigators plan to enroll more than 200 patients across five indications at multiple medical centers in Canada and the United States. IMV expects to initiate trial enrollment in the 4th quarter of 2018.

Click here to read the full press release.

The Conversation (0)
×